For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Osaka 599-8263
0 studies enrolling now · 31 studies all time
What they study most
Alzheimer's Disease, Alzheimer´s Disease, Autoimmune Disease, Axial Spondyloarthritis, Cardiovascular Diseases, Colorectal Cancer, Connective Tissue Disease, Diabetic Kidney Disease, Femur Neck Fracture, Gastroesophageal Junction Adenocarcinoma, Hepatocellular Carcinoma, Hypercholesterolemia
Studies at this site
- A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer — Running, not enrolling
- A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer — Completed
- A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein — Completed
- A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer — Completed
- A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia — Stopped early
- A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis — Completed
- A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis — Completed
- A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis — Completed
- A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis — Completed
- An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease — Stopped early
- Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo — Stopped early
- Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease — Stopped early
- A Study of Evacetrapib in High-Risk Vascular Disease — Stopped early
- A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease — Completed
- A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis — Completed
- A Study in Second Line Metastatic Colorectal Cancer — Completed
- A Study in Moderate to Severe Rheumatoid Arthritis — Completed
- A Study of LY3015014 in Participants With High Cholesterol — Completed
- A Study of Ixekizumab in Participants With Active Psoriatic Arthritis — Completed
- A Study of LY2127399 in Participants With Systemic Lupus Erythematosus — Completed
- An Open Label Study for Participants With Rheumatoid Arthritis — Stopped early
- A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement — Completed
- Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease — Stopped early
- A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate — Stopped early
- A Rheumatoid Arthritis Study in Participants — Completed
- Effect of Teriparatide on Hip Fracture Healing — Completed
- Effect of LY450139 on the Long Term Progression of Alzheimer's Disease — Completed
- Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo — Completed
- A Long-Term, Open-Label, Study on Schizophrenia — Stopped early
- Effect of LY2062430 on the Progression of Alzheimer's Disease — Completed
- Effect of LY2062430 on the Progression of Alzheimer's Disease — Completed